Cargando…
Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy
Background: Increasing evidence indicates a role for Epstein–Barr virus (EBV) in the pathogenesis of multiple sclerosis (MS). EBV-infected autoreactive B cells might accumulate in the central nervous system because of defective cytotoxic CD8(+) T cell immunity. We have previously reported results of...
Autores principales: | Ioannides, Zara A., Csurhes, Peter A., Douglas, Nanette L., Mackenroth, Gem, Swayne, Andrew, Thompson, Kate M., Hopkins, Tracey J., Green, Kerryn A., Blum, Stefan, Hooper, Kaye D., Wyssusek, Kerstin H., Coulthard, Alan, Pender, Michael P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005645/ https://www.ncbi.nlm.nih.gov/pubmed/33790852 http://dx.doi.org/10.3389/fneur.2021.652811 |
Ejemplares similares
-
Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
por: Pender, Michael P., et al.
Publicado: (2020) -
Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2014) -
Defective T-cell control of Epstein–Barr virus infection in multiple
sclerosis
por: Pender, Michael P, et al.
Publicado: (2017) -
Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2017) -
Correlations between macrophage/microglial activation marker sTREM-2
and measures of T-cell activation, neuroaxonal damage and disease severity in
multiple sclerosis
por: Ioannides, Zara A, et al.
Publicado: (2021)